An image of a pen pointing at a stock chart
Markets

Eli Lilly Cut to “Underperform” at Jefferies; Expects Alzheimer’s Drug to Fail in Trials (LLY)

Pharmaceuticals maker Eli Lilly & Co. ( LLY ) on Monday received a big downgrade from anlaysts at Jefferies & Co.

The firm slashed its rating on LLY from "Hold" to "Underperform" with a $35 price target, suggesting a big 21% downside to the stock's Friday closing price of $44.37.

Jefferies noted it expects Lilly's new Alzheimer's treatment, called solanezumab, to fail its pivotal studies. The company is expected to release data from recently-completed late-stage trials in August.

The analyst commented, "We expect that solanezumab will outright fail its pivotal studies in Alzheimer's disease…with only a 25 percent chance of being effective in a niche population."

Eli Lilly shares were mostly flat in premarket trading Monday.

The Bottom Line

Shares of Eli Lilly ( LLY ) have a 4.42% dividend yield, based on Friday's closing stock price of $44.37. The stock has technical support in the $40 price area. If the shares can firm up, we see overhead resistance around the $45-$47 price levels.

Eli Lilly & Co. ( LLY ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY

Other Topics

Stocks

Latest Markets Videos